Polaryx Therapeutics activated its first clinical trial site for a Phase 2 basket trial testing the oral candidate PLX-200 in children with Batten disease.
The study, known as the SOTERIA (NCT07740512) trial, evaluates the drug candidate across multiple pediatric conditions, including juvenile Batten disease (CLN3) and late infantile Batten disease (CLN2). Originally developed as a cholesterol-lowering medication, PLX-200 is now being investigated for these rare genetic disorders at Boys Town National Research Hospital in Nebraska, according to a company press release covered by Batten Disease News.
The trial is actively recruiting children ages 2 through 15 at the Nebraska hospital, which is located just west of Omaha. Boys Town serves as an affiliate center in the Batten Disease Support, Research, and Advocacy Foundation’s Batten Disease Clinical Center of Excellence Program, bringing specialized expertise in pediatric neurology to the study.
“For a study addressing several ultra-rare pediatric diseases, each participating center plays a meaningful role in identifying eligible patients and supporting families throughout the trial. We are pleased to begin this next phase with the experienced team at Boys Town as we work toward our first patient dosing milestone,” Alex Yang, chair and CEO of Polaryx, told Batten Disease News.
Expanding sites across the United States and Europe
Polaryx plans to broaden the geographic reach of the trial by adding five additional study sites across the United States. These centers are scheduled to begin screening participants in early 2027.
International expansion is also underway. Company executives said that regulatory applications have been submitted to authorities in the United Kingdom and the European Union to secure authorization for clinical sites abroad.
“With the first site activated, our immediate focus is on protocol-based screening and enrollment while continuing to prepare additional sites,” Will Charlton, chief medical officer of Polaryx, told Batten Disease News.
The site at Boys Town is led by Isabella Herman, MD, PhD, a pediatric neurologist and neurogeneticist.
“We are incredibly proud to be the first site activated for this trial, bringing innovative research closer to the families who need it most,” Herman told Batten Disease News.
Targeting lysosomal storage disorders
Both juvenile and late infantile Batten disease are classified as lysosomal storage disorders. These genetic conditions disrupt the function of cellular compartments called lysosomes, which normally act as biological garbage disposals that break down molecular waste.
When lysosomes fail to process specific types of molecular waste adequately, the toxic material accumulates inside cells and drives progressive neurological symptoms. PLX-200 aims to address this cellular dysfunction by repurposing the existing drug compound to restore waste clearance in affected pediatric patients.
Trial expansion sites await activation dates
While the Boys Town site is currently enrolling participants and five additional U.S. locations are slated to begin screening next year, exact activation dates for individual domestic expansion sites remain unannounced. Regulatory authorities in the U.K. and the European Union have not yet issued a final decision regarding the company's applications to open European trial locations.
“We are grateful for the commitment of the investigators, clinical teams and families who make rare disease research possible,” Charlton told Batten Disease News.
Worth a look